Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic
polychemotherapy followed by local surgical therapy and then postoperative (adjuvant)
chemotherapy, long-term, disease-free survival can be achieved in 60- 70% of osteosarcoma
patients. However treatment options for osteosarcomas, especially in the setting of
metastatic or unresectable disease, are very scarce. Apatinib has been proved to be an
effective agent to prolong progression-free survival in advanced osteosarcoma. But after 4-6
months' treatment, secondary resistance always occurred with musculoskeletal lesions'
progression or new metastasis.
Nowadays giving therapeutic doses of IE concurrently with anti-angiogenesis tyrosine kinase
inhibitors is a conceptually attractive strategy for treating patients with refractory
osteosarcoma according to prospective trial of lenvatinib +IE reported by Gaspar et al at
2019 ESMO and 2020 ESMO. Thus This study was designed to review our experience in real world
for off-label use and characterize the toxicity profile of concurrent apatinib+IE and IE
alone in patients with relapsed or refractory osteosarcoma.